SCHEMBL790781

SCHEMBL790781

CNN1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27433091 0.96
SCHEMBL15388363 0.92
SCHEMBL528887 0.92
SCHEMBL528404 0.89
SCHEMBL6670546 0.89 CARM1 (0.33)
Bromide SCHEMBL4361146 0.89
SCHEMBL25769149 0.89 CARM1 (0.33)
Hydrochloric Acid SCHEMBL1026800 0.89
SCHEMBL1092361 0.89
Bromide SCHEMBL7065182 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
US-20250368666-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES INC (US) 2025-12-04 US disclosed
US-20250340533-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES INC (US) 2025-11-06 US disclosed
US-20250320213-A1 Nitrogen-Containing Heterocyclic Compounds PFIZER INC. (US) 2025-10-16 US disclosed
US-12264149-B2 Indazole compounds as kinase inhibitors TYRA BIOSCIENCES, INC. (US) 2025-04-01 US disclosed
US-20240317775-A1 H4 Antagonist Compounds NXERA PHARMA UK LIMITED (GB) 2024-09-26 US disclosed
US-12071428-B2 Indazole compounds as kinase inhibitors TYRA BIOSCIENCES, INC. (US) 2024-08-27 US disclosed
WO-2024138206-A1 FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF FRONTIER MEDICINES CORPORATION (US) 2024-06-27 WO disclosed
US-20240208941-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES, INC. 2024-06-27 US disclosed
US-20240109865-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS TYRA BIOSCIENCES, INC. 2024-04-04 US disclosed
WO-2012037298-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
WO-2011076878-A1 AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS PALAU PHARMA, S.A. (ES) 2011-06-30 WO disclosed
US-20100298289-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2010-11-25 US disclosed
US-20100113420-A1 PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS PALAU PHARMA, S.A. (ES) 2010-05-06 US disclosed
US-20100035863-A1 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions UCB PHARMA, S.A. (BE) 2010-02-11 US disclosed
WO-2008101660-A1 SPIROCYCLIC CYCLOHEXANE DERIVATIVES Grünenthal GmbH (DE) 2008-08-28 WO disclosed
EP-0606382-B1 1,8-BENZONAPHTHYRIDINE DERIVATIVES AND ANTIMICROBIAL COMPOSITIONS BELLON LABOR SA ROGER (FR) 1998-05-13 EP disclosed
EP-0606382-A1 1,8-BENZONAPHTHYRIDINE DERIVATIVES AND ANTIMICROBIAL COMPOSITIONS LABORATOIRE ROGER BELLON (FR) 1994-07-20 EP disclosed
WO-1993007144-A1 1,8-BENZONAPHTHYRIDINE DERIVATIVES AND ANTIMICROBIAL COMPOSITIONS LABORATOIRE ROGER BELLON (FR) 1993-04-15 WO disclosed
EP-0536035-A1 1,8-Benzonaphthyridine derivatives and antimicrobial compositions LABORATOIRE ROGER BELLON (FR) 1993-04-07 EP disclosed